Show simple item record

dc.contributor.authorHussain, SAen_US
dc.contributor.authorBirtle, Aen_US
dc.contributor.authorCrabb, Sen_US
dc.contributor.authorHuddart, Ren_US
dc.contributor.authorSmall, Den_US
dc.contributor.authorSummerhayes, Men_US
dc.contributor.authorJones, Ren_US
dc.contributor.authorProtheroe, Aen_US
dc.coverage.spatialNetherlandsen_US
dc.date.accessioned2019-06-24T08:59:24Z
dc.date.issued2018-12en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/31158093en_US
dc.identifierS2588-9311(18)30075-0en_US
dc.identifier.citationEur Urol Oncol, 2018, 1 (6), pp. 486 - 500en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3271
dc.identifier.eissn2588-9311en_US
dc.identifier.doi10.1016/j.euo.2018.05.011en_US
dc.description.abstractCONTEXT: A number of PD-1/PD-L1 inhibitors have recently been approved for use in patients with locally advanced or metastatic urothelial carcinoma (UC) on the basis of results from several clinical trials. OBJECTIVE: To review the evidence from these trials and consider what it means for the use of these drugs in first-line and post-platinum settings in real-life clinical practice. EVIDENCE ACQUISITION: PubMed was searched for full reports of clinical trials of single-agent PD-1/PD-L1 inhibitors in advanced UC. Twelve publications were included. EVIDENCE SYNTHESIS: Responses to PD-1/PD-L1 inhibitors appear to be durable but are only achieved in 17-26% of patients. These drugs offer different toxicity and efficacy profiles to standard chemotherapy regimens. This should be considered when choosing a treatment strategy for each patient. CONCLUSIONS: PD-1/PD-L1 inhibitors represent a major step forward in the management of advanced UC, although several questions remain regarding their optimal use in routine clinical practice. A validated predictive biomarker of response is yet to be defined, and this is perhaps the most significant unmet need for currently available drugs. PATIENT SUMMARY: We reviewed the results from clinical trials that investigated how well certain types of anticancer drugs called PD-1/PD-L1 inhibitors worked in patients with bladder cancer. We found that more research is required to identify (1) the factors that might predict which patients with bladder cancer will respond to PD-1/PD-L1 inhibitors and (2) the optimum duration of treatment with these drugs.en_US
dc.format.extent486 - 500en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectAtezolizumaben_US
dc.subjectAvelumaben_US
dc.subjectBladder canceren_US
dc.subjectDurvalumaben_US
dc.subjectImmune checkpoint inhibitoren_US
dc.subjectImmunotherapyen_US
dc.subjectNivolumaben_US
dc.subjectPembrolizumaben_US
dc.subjectTransitional cell carcinomaen_US
dc.subjectUrothelial carcinomaen_US
dc.titleFrom Clinical Trials to Real-life Clinical Practice: The Role of Immunotherapy with PD-1/PD-L1 Inhibitors in Advanced Urothelial Carcinoma.en_US
dc.typeJournal Article
dcterms.dateAccepted2018-05-30en_US
rioxxterms.versionofrecord10.1016/j.euo.2018.05.011en_US
rioxxterms.licenseref.startdate2018-12en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfEur Urol Oncolen_US
pubs.issue6en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.publication-statusPublisheden_US
pubs.volume1en_US
pubs.embargo.termsNot knownen_US
icr.researchteamClinical Academic Radiotherapy (Huddart)en_US
dc.contributor.icrauthorHuddart, Roberten_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/